HB Wealth Management LLC Has $496,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

HB Wealth Management LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,757 shares of the medical equipment provider’s stock after purchasing an additional 400 shares during the quarter. HB Wealth Management LLC’s holdings in Zimmer Biomet were worth $496,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ZBH. OLD Point Trust & Financial Services N A bought a new stake in Zimmer Biomet in the fourth quarter valued at $26,000. Ables Iannone Moore & Associates Inc. bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $30,000. Naples Money Management LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $35,000. Activest Wealth Management grew its holdings in shares of Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 153 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.5 %

Shares of NYSE ZBH traded up $0.52 during mid-day trading on Friday, reaching $107.10. 342,633 shares of the company’s stock were exchanged, compared to its average volume of 1,496,704. The firm has a market capitalization of $22.03 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 1.92 and a beta of 1.01. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. The business has a fifty day simple moving average of $114.14 and a 200 day simple moving average of $120.85. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $144.13.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same period last year, the company earned $1.89 earnings per share. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s dividend payout ratio is 20.78%.

Analyst Ratings Changes

ZBH has been the topic of several research analyst reports. Barclays decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Piper Sandler cut Zimmer Biomet from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $140.00 to $115.00 in a report on Monday. Truist Financial cut their price target on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a research note on Friday, May 3rd. The Goldman Sachs Group began coverage on Zimmer Biomet in a research note on Thursday, May 30th. They set a “neutral” rating and a $129.00 price target on the stock. Finally, Evercore ISI cut their price target on Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $131.76.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.